Raza Bokhari

Dr. Raza Bokhari $MDCX CEO along with $MDCX family and friends rings the opening bell to celebrate one year anniversary on Nasdaq.

Ringing the opening bell to celebrate ⁦@MedicusLtd⁩ one year anniversary ⁦@NasdaqExchange⁩

⁦@R_Bokhari⁩ $MDCX Chairman & CEO to ring the opening at Nasdaq on Jan 22nd 2026!!

Dr. Raza Bokhari $MDCX CEO presenting at Biotech Showcase San Francisco, CA.

@R_Bokhari $MDCX CEO on @visitthecapitol meeting with @RepDaveJoyce Co-chair of the Skin Cancer Caucus and @RepBuddyCarter Chair of Cancer Survivor Caucus

@R_Bokhari $MDCX #CEO @WhiteHouse

Medicus Pharma (MDCX) Price Target Increased by 13.56% to 22.78 | Nasdaq nasdaq.com/articles/medic…

Dr. Raza Bokhari | 100 Dynamic Leaders of 2025 | Exeleon Magazine exeleonmagazine.com/dr-raza-bokhar…

Dr. Raza Bokhari | 100 Dynamic Leaders of 2025 | Exeleon Magazine exeleonmagazine.com/dr-raza-bokhar…

First UAE Patient Enrolled in Medicus' Trial for Non-Invasive BCC Therapy | Dermatology Times dermatologytimes.com/view/first-uae…

Medicus Pharma Focuses on Regulatory Efficiency and Scientific Development usatoday.com/story/special/…

Antev in the news following Medicus Pharma acquisition! Potential $6B market opportunity. @R_Bokhari Full story: bioxconomy.com/partnering/ant…

Dr Raza Bokhari, CEO of $MDCX, to present at Family Office Summit in Dubai. Surrounding the theme “Unlocking the $1 trillion Wealth Transfer”. Dr. Bokhari, in his presentation, will highlight innovations in biotech/life sciences, the role of artificial intelligence (AI) in drug development and U.A.E. human genome project as an "untapped differentiator". @R_Bokhari Full press release: accessnewswire.com/newsroom/en/he…

$MDCX #CEO ⁦@R_Bokhari⁩ speaking at Family Office Summit #Dubai

$MDCX CEO Dr. Raza Bokhari provides update on type C FDA meeting positive feedback; FDA nod to follow 505(b)(2) regulatory pathway to commercialize D-MNA to treat BCC of the Skin presenting ~$2 billion in potential market opportunity. The outlook of $MDCX today couldn’t be more promising. @R_Bokhari Watch full interview: proactiveinvestors.com/companies/news…

$MDCX receives FDA nod to follow 505(b)(2) regulatory pathway to develop and commercialize  D-MNA to treat BCC of the Skin. This positive feedback from a type C meeting with the FDA is a game changer with substantial time and cost savings. We are getting increasingly confident that our novel D-MNA treatment may become commercially available sometime in 2027 to leverage ~$2 billion in potential market opportunity. Full press release: accessnewswire.com/newsroom/en/he…

$MDCX completed a non-dilutive $8.0 million debenture financing. The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~ $6 billion in potential market opportunity. Full press release: accessnewswire.com/newsroom/en/he… @R_Bokhari

New interview with $MDCX CEO--Skinject expanding  its phase 2 trial beyond the shores of the United States; update on Antev acquisition and Teverelix, a next generation GnRH antagonist, focused on developing treatment of advanced prostate cancer patients with high CV risk profile and prevent relapse of Acute urinary retention (AURr). Full interview: proactiveinvestors.com/companies/news… @R_Bokhari

$20B Skin Cancer Market Eyes Non-Surgical Solutions—@MedicusLtd Leads Innovation | Airing on @CNBC What if investing in cancer care meant backing a future where treatment is non-invasive and nearly painless? Medicus Pharma (NASDAQ: MDCX) is breaking ground with a solution that delivers chemotherapy directly to tumor sites, offering a surgery-free alternative. Advancing through Phase 2 studies Global skin cancer treatment market set to surpass $20B by 2030 Cost-effective, patient-friendly innovation As demand for accessible and less invasive cancer therapies accelerates, Medicus Pharma is positioning itself at the forefront of oncology innovation. 📺 Learn more: b-tv.com/post/medicus-p…